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SUMMARY
Background: The influences of genetic and environmental factors form a clinical picture of type 2 diabetes mel-
litus. Genetic studies of type 2 diabetes mellitus become increasingly important. The knowledge of the molecu-
lar background of type 2 diabetes has been growing rapidly over recent years. One of the forms of the disease de-
fined on the molecular level is maternally inherited type 2 diabetes mellitus. This diabetes, which is frequently
accompanied by hearing impairment or deafness (maternally inherited diabetes with deafness-MIDD), was lin-
ked with sequence differences in mitochondrial DNA. The most frequent cause of MIDD is A3243G substitu-
tion in a mitochondrial tRNALeu gene. While this mutation was identified in different races in several popula-
tions, it is still important and valuable to evaluate its prevalence in various ethnic groups. The aim of the project
was to determine the prevalence of A3243G substitution in a mitochondrial tRNALeu gene among Polish diabe-
tic subjects. 
Material and methods: In total 129 individuals, with type 2 diabetes and 12 with gestational diabetes were selec-
ted for this study. Two techniques based on restriction fragment length polymorphism (RFLP) method were
used to screen for A3243G mutation. In the first approach, non-radioactive PCR reactions of mitochondrial
DNA region of interest were performed using DNA of the study participants. This was followed by Apa I restric-
tion enzyme digestion of the PCR product. Subsequently an electrophoretic separation was done on 2% agarose
gel with ethidium bromide staining. In the second, more sensitive, modification of RFLP, [a32P]dCTP was
used for internal primer labeling and the electrophoresis was done on acrylamide gel. A positive sample was
used to control the quality of the genotyping. 
Results: In both approaches none of the samples, except for the positive control, showed the evidence of the
G variant. 
Conclusions: In summary, the A3243G mutation in mitochondrial tRNALeu gene is not a frequent cause of dia-
betes in the Polish population. Further screening of enlarging study group is necessary to fully determine the pre-
valence of this mutation in our population. This, together with the search for other mitochondrial mutations,
should allow to fully determine the prevalence of MIDD and its specific molecular background in the Polish
population.
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BACKGROUND
A clinical picture of type 2 diabetes mellitus is cre-
ated by joint influences of genetic and environ-
mental factors. Two major pathophysiological de-
fects coexist in this disease: impairment of insulin
secretion by b-cells and decreased insulin sensitivi-
ty in peripheral tissues [1,2,3]. Genetic studies of
type 2 diabetes mellitus become increasingly im-
portant due to their scientific, prognostic, prophy-
lactic and also therapeutic significance, however
the molecular background of the disease still rema-
ins mostly unknown. So far several different genes
have been associated with autosomal dominant ty-
pe 2 diabetes mellitus, whose early forms are
known in literature as MODY (Maturity-Onset Dia-
betes of the Young) and are characterized by b-
-cells insulin secretion defect [4,5]. Autosomal do-
minant type 2 diabetes mellitus occurs in families
in several subsequent generations with high pene-
trance among the carriers of the mutations. Its dif-
ferent forms show some evidence of clinical hete-
rogeneity [4]. For example, mutations identified in
glucokinase gene are responsible for relatively mo-
dest clinical form of the disease. Glucokinase is
a key enzyme of b-cells metabolism which cataly-
ses phosphorylation of glucose to glucose-6pho-
sphate. It leads to ATP synthesis and eventually,
through the changes in ionic channels, to the insu-
lin output. More severe autosomal dominant type
2 diabetes is associated with mutations in transcrip-
tion factors, which are directly or indirectly invo-
lved in the insulin gene expression. Mutations in
HNF (hepatocyte nuclear factor)-1a were identi-
fied as the most frequent cause of MODY in seve-
ral populations [4]. Recently, two susceptibility ge-
nes for the common forms of type 2 diabetes have
been identified [6]. The first one is peroxisome
proliferator-activated receptor-g. The common
Pro12Ala polymorphism in this gene was found to
be associated g with type 2 diabetes in several eth-
nic groups and may be responsible for as much as
25% of this disease [6]. The second gene is calpain
10, a member of a large family of intracellular pro-
teinases [7]. They are essential for multiple cellular
functions, since the processing activity of these en-
zymes makes it possible to modulate directly the
activities and structural properties of other proteins
[8]. The specific mechanism through which some
polymorphisms in PPARg and calpain 10 genes in-
crease the risk of type 2 diabetes development
must yet be discovered.
Another form of the disease defined on the mole-
cular level is maternally inherited type 2 diabetes
mellitus. This form of diabetes was linked with se-
quence differences in mitochondrial DNA [9]. It is
characterized by early age at diagnosis, usually in
3—5 decade of life, and impairment in insulin se-
cretion. This form of diabetes is frequently accom-
panied by impaired hearing or deafness (maternal-
ly inherited diabetes with deafness-MIDD) [10,11].
There were plural mutations described in mito-
chondrial DNA that resulted in a diabetic phenoty-
pe. The most frequent one is A3243G substitution
in a mitochondrial leucyl tRNA gene [11]. This mu-
tation was originally identified in MELAS (mito-
chondrial encephalopathy, lactic acidosis, and stro-
ke like episodes) syndrome and it was later linked
with different phenotypes, including type 2 diabe-
tes among the others [12]. While this mutation was
described in different races in several populations
[13—19], it is still important and valuable to evalu-
ate its prevalence in various ethnic groups.
The aim of our study was to determine the preva-
lence of A3243G substitution in a mitochondrial
tRNALeu gene in Polish diabetic subjects.
MATERIAL AND METHODS
Subjects
In total 139 individuals were selected for this stu-
dy. Of them, there were 127 patients with type 2
diabetes and 12 with gestational diabetes. The cur-
rent WHO criteria and definitions were used [20].
Subjects were classified as having type 2 diabetes if
they were initially treated with diet only or oral hy-
poglycemic agents for a minimum of 2 years. Pa-
tients answered a questionnaire including age at
diagnosis of diabetes, diabetes therapy, family hi-
story of diabetes, and accompanying diseases. The
study was conducted in accordance with the gu-
idelines of the Declaration of Helsinki and appro-
ved by the Ethics Committee of Jagellonian Univer-
sity, Krakow, Poland.
Detection of the A3243 mutation 
in the mitochondrial tRNALeu gene
DNA was isolated from peripheral blood lympho-
cytes of the patients selected for the study. To iso-
late DNA a novel guanidine-detergent procedure
(DNAzol Reagent, GIBCO) was used [21]. The
extraction solution was used for this purpose ac-
cording to manufacturerÕs guidelines.
Primers for mtDNA region of interest were used as
previously published [10] and PCR reactions were
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performed using DNA of the study participants. Two
different techniques based on restriction fragment
length polymorphism (RFLP) method were used to
screen for A3243G mutation. In the first approach,
the volume of PCR reaction was 20 microliters. Each
PCR reaction contained 50 ng of genomic DNA, 20
pmol of each primer, 200 mM dNTP, 1.0 mM MgCl2
and 0.5 units of Display Taq (Display Systems Bio-
tech) with 2.0 ml of 10x PCR buffer. The following
conditions were used on 2400 Perkin-Elmer Ther-
mocycler: after 5 min of a denaturation step at
94¡C, samples were subjected to 39 cycles of 1 min
at 94¡C for denaturating, 1 min at 55¡C of annealing
temperature, and 1 min at 72¡C for elongation. This
was followed by Apa I restriction enzyme digestion
of the PCR product at 25¡C for 8 h. Subsequently an
electrophoretic separation was done on 2% agarose
gel with ethidium bromide staining.
In the second technique, the volume of PCR reac-
tion was 20 microliters. Each PCR reaction conta-
ined 10 ng of genomic DNA, 1.5 pmol of each pri-
mer, 2 umol of dATP, dGTP, dTTP, 0.025 umol
dCTP, 0.1 mmol/l MgCl2, 0.07uCi [a32P]dCTP
(800Ci/mmol) for internal primer labeling and 0.3
U of Taq polymerase. The cycles were done on
a model PTC-100 Thermal Cycler (MJ Research,
Waltham, MA, USA). The initial denaturation step
at 95¡C (5 minutes) was followed by 34 cycles of
denaturation (45 s at 95¡C), annealing (45 s at
59¡C) and extension (60 s at 72¡C). The PCR pro-
duct was digested with Apa I restriction enzyme at
37¡C for 8h. Gels were then dried and exposed to
films at —70¡C for 1 day. After the digestion of PCR
product, 2 volumes of sequencing stop solution
were added to the PCR product. The mixture was
heated at 95¡C for 5 min, and 5 ul of the denatura-
ted product was loaded onto 5% polyacrylamide
DNA sequencing gels and resolved electrophoreti-
cally in 0.6xTBE at 100 W constant current. Dried
gels were exposed to X-ray films for 12 h without
intensifying screen. Positive sample was used to
control the quality of the genotyping.
RESULTS
On average the diabetic patients were 44.7–11.6
years old at the time of the diagnosis and the mean
duration of their disease was 13 years. Of 139 indi-
viduals, 61% had a positive family history of diabe-
tes, including 30% with maternal history of diabe-
tes, 14% with paternal history of diabetes. Both pa-
rents being diagnosed with diabetes was reported
by 1% of the participants.
15 examined patients were probands from the fa-
milies that fulfilled MODY criteria: diabetes in
three generations and at least one patient with age
at onset of < 25 years. In one family with maternal
pattern of diabetes inheritance two individuals re-
ported the diagnosis of the hearing impairment.
None of the patients, except for positive quality
control sample, showed the evidence of the G va-
riant. This applies to both techniques used in this
study: non-radioactive PCR with subsequent elec-
trophoresis on the ethidium bromide stained aga-
rose gel and the confirmation by more sensitive ap-
proach: radioactive PCR with electrophoresis on
the acrylamide gel.
DISCUSSION
In this paper, we report the results of the search for
A3243G mutation in mitochondrial tRNALeu gene
in subjects with type 2 and gestational diabetes in
a Polish population. None of the individuals was
identified as a carrier of this mutation. Below, we
discuss the contribution of this mutation to diabe-
tes in different populations and the methods,
which can be used to screen for A3243G mutation.
The knowledge of the molecular background of
the type 2 diabetes has been growing rapidly over
last decade. One of the first sequence differences
linked to this disease were mutations in mitochon-
drial DNA [9]. The mechanism of the mitochon-
drial mutations affecting glucose homeostasis is un-
certain. Most likely, the glucose sensoring function
of the b cells or their ability to produce insulin are
affected. The impairment of insulin secretory capa-
city assessed by the oral glucose tolerance test, glu-
cagon test and C-peptide excretion was described
in patients with MIDD [22]. This observation was
confirmed by hyperglycaemic and euglycaemic
clamp studies [23,24]. Early failure of sulphonylu-
rea therapy and a clinical phenotype similar to ty-
pe 1 diabetes frequently observed among patients
with MIDD suggest the reduction of b-cell mass in
these patients. Autopsy data showed the atrophy of
pancreatic islets and the reduction of the number
of b cells among patients with MELAS [11]. In ge-
neral, the additional clinical features that may sug-
gest a defect in mitochondrial DNA include mul-
tiorgan disorder (ECG abnormality, proteinuria,
neuromuscular signs), and elevated lactate or lacta-
te/puryvate ratio [11]. Cardiovascular problems,
hypertension, nephropathy and spontaneous abor-
tions have been observed among these patients.
[12,26—28]. However, it is not clear, whether these
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are true diabetic complications or clinical features
related to the 3243 mutation itself.
The majority of MIDD cases were associated with
A3243G mutation in tRNALeu gene [11]. The frequ-
ency of this mutation reported in different popula-
tions varies. The prevalence above 1% of unselec-
ted type 2 cases was found in Japanese and Dutch
populations [13,16,17], while in Australian ethni-
cally mixed population it reached about 0.5% [18].
The data coming from a large British UKPDS study
suggest low frequency of G variant (about 0.2%)
among type 2 diabetes patients in this population
[15]. On the other hand, in selected Scandinavian
groups of patients with early onset diabetes (age at
diagnosis< 40) and positive family history,
A3243G mutation represented the cause of the di-
sease in 2.6% [19].
We screened a large group of Polish type 2 diabetic
patients together with a small number of gestational
diabetes patients. It is well known that women who
were diagnosed with gestational diabetes are at
high risk of type 2 diabetes, so the inclusion of this
subgroup seems to be well justified [20]. Our results
suggest that A3243G mutation is not a frequent
cause of diabetes in the Polish population. Further
screening is required to fully determine whether
this mutation contributes to the existence of diabe-
tes in our population. This, together with the search
for other mitochondrial mutations, will allow to fully
determine the prevalence of MIDD and its specific
molecular background in the Polish population. In
our study group, at least one family appears clearly
to have diabetes associated with mitochondrial
DNA mutation, since it shows maternal pattern of
inheritance and in addition two diabetic patients
were diagnosed with hearing impairment.
There are several possible methods of screening for
this mutation. In the first report of van den Ouwe-
land et al. direct sequencing was initially used. Sin-
ce G variant creates a new restriction site for Apa I,
techniques based on RLFP were subsequently de-
veloped [10]. The simplest approach is to separate
the digested PCR product on the agarose gel with
etidium bromide staining. However, this may not
be sensitive enough to detect the mutation if the
percentage of mutant mitochondrial DNA is low. It
was reported that this method might omit as much
as one third of the heterozygous samples in com-
parison to more sensitive acrylamide electrophore-
sis followed by silver staining [21]. However, the
ªgold standardÒ remains radioactive PCR and elec-
trophoresis of digested PCR product on acrylamide
sequencing gel [10,19]. It seems very likely that, at
least in part, the discrepancies in frequency of in-
vestigated variant of leucyl tRNA gene between the
populations may be attributed to different sensitivi-
ty of screening methods. In our study however, the
initial negative results of the less sensitive method
were confirmed by reference modification.
CONCLUSIONS
In summary, the A3243G mutation in mitochon-
dria tRNALeu gene is not a frequent cause of diabe-
tes in the Polish population. Further screening of
enlarged study group is necessary to fully determi-
ne the prevalence of this mutation in our popula-
tion. This, together with the search for other mito-
chondrial mutations, will help to fully determine
the prevalence of MIDD and its specific molecular
background in the Polish population.
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